Aurobindo Pharma share price falls as FY26 margins tighten

What triggered the latest drop in Aurobindo Pharma stock

Aurobindo Pharma shares saw sharp intraday declines across multiple sessions as investors reacted to a mix of quarterly updates, regulatory headlines, and broader midcap volatility. The stock fell as much as 7% after the company announced its March 2026 quarter results, even though net profit rose marginally, as the market focused on margin contraction. In another session, the shares fell nearly 5% after reports said the US Food and Drug Administration (USFDA) issued several observations at one of the company’s units. The selling also coincided with profit booking in pharma and PSU stocks and weakness in the NIFTYMIDCAP150 index, where Aurobindo was among the day’s top losers.

March 2026 quarter: US formulation weakness in focus

A key point flagged by investors was the continued weakness in the US formulation business during the March 2026 quarter. The company said US formulation revenue fell 13% year-on-year to ₹3,543 crore from ₹4,072 crore. Aurobindo attributed the impact primarily to lower transient sales. The company also stated that the US formulation business accounted for 40% of consolidated revenue in the quarter, highlighting how sensitive consolidated performance can be to US pricing and demand conditions.

Q3FY26 (December 2025 quarter): revenue growth but mixed regional trend

The December 2025 quarter (Q3FY26) numbers showed single-digit growth at the consolidated level, but the regional split remained uneven. Aurobindo reported 8.4% year-on-year growth in revenue to ₹8,646 crore, with softness in the US cited as a key factor because the region contributed 43% of revenues. US revenue grew 2% year-on-year to ₹3,739 crore during the quarter, while Europe formulations revenue rose 27.4% year-on-year to ₹2,703 crore. Growth markets revenue was flat year-on-year at ₹865 crore. On profitability, EBITDA grew 9% year-on-year to about ₹1,773 crore and EBITDA margin increased 11 basis points to 20.5%. Profit after tax (PAT) increased 7.6% year-on-year to ₹910 crore.

Q1FY26 (June quarter): profit decline and margin contraction

In Q1FY26, the company reported a year-on-year decline in consolidated profit, again linked to weaker US and API performance. Net profit fell 10.2% year-on-year to ₹824 crore, compared with ₹918 crore (also reported as ₹919 crore in another update) in the year-ago quarter. Revenue from operations rose 4% year-on-year to ₹7,868 crore from ₹7,567 crore. On operating performance, one earnings summary reported EBITDA at ₹1,602.9 crore versus ₹1,619.4 crore, with EBITDA margin contracting to 20.4% from 21.4%. Another disclosure referenced EBITDA before R&D at ₹1,967 crore versus ₹1,936 crore, with margin before R&D declining 84 basis points to 24.8% from 25.6%.

Segment performance: US flat to down, Europe and growth markets positive

The June quarter segment numbers showed the same divergence between geographies. US formulations revenue marginally declined 1.9% year-on-year to ₹3,488 crore. Europe formulations revenue increased 18% year-on-year to ₹2,338 crore, and growth markets revenue increased 8.8% to ₹772 crore. ARV revenue increased 55.2% to ₹355 crore, while API revenue decreased 16% to ₹916 crore. The company’s R&D expenditure stood at ₹367 crore, accounting for 4.7% of total revenues.

Regulatory and operational overhang: USFDA observations and plant costs

Regulatory updates also influenced sentiment. The stock fell as much as 4.85% to ₹1,129.2 per share on a day when reports said the USFDA issued several observations at a unit, described as the biggest intraday fall since February 10 for that period. Separately, a brokerage note cited recent hiccups related to manufacturing plant issues and tariff uncertainties as contributors to earnings volatility. The brokerage said Aurobindo delivered lower-than-expected performance for Q1FY26, with EBITDA and PAT missing its estimates by 7% and 8% respectively, and cut earnings estimates by 8% and 7% for FY26 and FY27.

How the sell-off showed up on the screen

The declines were steep enough for the stock to repeatedly feature among top losers in its segment. Aurobindo Pharma fell 7.52% to ₹1,111.40 per share at 15:07:00 PM, placing it among the top losers on the NIFTYMIDCAP150. In another session, it declined 6.46% to ₹1,125.90, again cited among the top losers on the Nifty Midcap 150. After Q3FY26 results, the share price hit an over three-month low of ₹1,110.55, falling 8% in intraday trade, and was quoted around ₹1,114.30 at 02:46 PM while the BSE Sensex was up 0.22%. After Q1FY26 numbers, it fell over 2% to an intraday low of ₹1,067.3.

Key numbers snapshot

Market impact: why investors reacted despite revenue growth

The price action suggests the market is currently more sensitive to mix and margins than to top-line growth alone. US formulations and API trends mattered because they directly influenced operating leverage, and both were reported as weak or under pressure across FY26 updates. At the same time, Europe formulations and growth markets provided offsets, but not enough to prevent margin contraction from becoming the dominant narrative. Regulatory headlines such as USFDA observations added another layer of risk assessment for investors, especially when the stock was already seeing profit booking in a volatile midcap tape.

Analysis: what to watch next based on disclosed facts

Three datapoints stand out from the disclosures. First, the US business remains large, with the US at 43% of revenues in Q3FY26 and the US formulation business at 40% of consolidated revenue in the March 2026 quarter, so even small swings in US performance can reshape consolidated margins. Second, segment dispersion is widening, with Europe showing double-digit growth while US formulations were flat to down in Q1FY26. Third, operating costs linked to newer plants and pricing headwinds in APIs were cited by a brokerage as earnings drags in Q1FY26, reinforcing why margin commentary is driving near-term stock reactions.

Conclusion

Aurobindo Pharma’s recent share price declines were driven by a combination of margin pressure, US business softness, and regulatory overhang, even as parts of the portfolio such as Europe and growth markets showed momentum. Investors are likely to track subsequent updates on US formulations performance, API pricing headwinds, and any follow-through disclosures related to the reported USFDA observations.